LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Friday.

Several other equities research analysts have also issued reports on LIVN. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday, January 28th. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Finally, Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Trading Up 0.1 %

NASDAQ:LIVN opened at $47.68 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market capitalization of $2.59 billion, a P/E ratio of 113.52 and a beta of 1.00. The stock’s 50 day moving average price is $48.30 and its 200 day moving average price is $49.56. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its stake in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC increased its position in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division raised its stake in shares of LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares in the last quarter. Captrust Financial Advisors bought a new position in LivaNova in the third quarter worth $217,000. Finally, Sanctuary Advisors LLC acquired a new stake in LivaNova during the third quarter worth $219,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.